Arsenic promotes hippocampal neuronal damage inducing cognitive impairments. However, mechanism arbitrating arsenic-mediated cognitive deficits remains less-known. Here, we identified that chronic exposure to environmentally relevant doses of arsenic increased apoptosis, characterized by caspase-3 activation, poly(ADP-ribose) polymerase cleavage and Terminal deoxynucleotidyl transferase dUTP nick-end labeling of rat hippocampal neurons, marked by NeuN. Investigating apoptotic mechanism through in vivo and in vitro studies revealed that arsenic promoted bone morphogenetic protein-2 (BMP2) expression, supported by increased BMP-receptor2 (BMPR2) and p-Smad1/5 in hippocampal neurons. BMP2-silencing and treatment with BMP antagonist, noggin, attenuated the arsenic-induced apoptosis and loss in hippocampal neurons. We then investigated whether BMP2/Smad signaling stimulated neuronal apoptosis independently or required other intermediate pathways. We hypothesized participation of brain-derived neurotrophic factor (BDNF) that promotes neuronal survival. We identified an arsenic-mediated attenuation of BDNF-dependent TrkB signaling, and observed that co-treatment with recombinant-BDNF reinstated BDNF/TrkB and reduced neuronal apoptosis. To probe whether BMP2/Smad and BDNF/TrkB pathways could be linked, we co-treated arsenic with noggin or recombinant BDNF. We detected a noggin-mediated restored BDNF/TrkB, while recombinant-BDNF failed to affect BMP2/Smad signaling. In addition, we found that TrkB-inhibitor, K252a, nullified noggin-induced protection, proving the necessity of a downstream reduced BDNF/TrKB signaling for BMP2/Smad-mediated apoptosis in arsenic-treated neurons. We further related our observations with cognitive performances, and detected noggin-mediated restoration of transfer latency time and learningmemory ability for passive avoidance and Y-Maze tests respectively in arsenic-treated rats. Overall, our study proves that arsenic promotes hippocampal neuronal apoptosis through an up-regulated BMP2/Smad-dependent attenuation of BDNF/ TrkB pathway, inducing cognitive deficits.
Arsenic is a major environmental toxicant, affecting above 200 million people world-wide (Bakhat et al., 2017; Tolins et al., 2014) . Contaminated drinking-water is a key route of human exposure to arsenic, which results in cognitive dysfunction and prominent learning and memory disabilities (RodriguezBarranco et al., 2016; Tolins et al., 2014) . Arsenic is capable of crossing blood-brain barrier, and its enhanced level within the brain deregulates neurocellular signaling pathways and functions Rai et al., 2010; Xi et al., 2010) .
The hippocampus sustains memory functions, and hippocampal neuronal atrophy forms an important reason for cognitive impairments (Bruel-Jungerman et al., 2007; Hollands et al., 2016; Lazarov and Hollands, 2016) . Enhanced apoptosis, triggering reduced viability and increased loss of hippocampal neurons, plays a key role in the decline of learning memory performances (Kuang et al., 2014; Lin et al., 2016) . Matured neurons typically identify with the neuronal nuclear antigenneuron marker (NeuN), and increased apoptosis within NeuNexpressing hippocampal neuron associates with aberrant neurological functions and cognitive deficits (Du et al., 2016; Yang et al., 2016) . Few reports claimed altered synaptic structure, N-methyl-D-aspartate receptor gene expression and cholinergic dysfunctions within the hippocampus as key reasons for arsenic-induced cognitive deficits (Chandravanshi et al., 2014; Huo et al., 2015; Luo et al., 2009) . A study demonstrated arsenic-induced preliminary morphological alterations and apoptosis within the hippocampus (Kaler et al., 2013) , and a second report indicated its connection with learning-memory dysfunction (Flora et al., 2009) . However, thorough information, through both in vivo and in vitro studies, about the link between apoptosis, hippocampal neuronal loss and predominantly the underlying mechanism following environmentally relevant arsenic exposure is less-known. Moreover, a direct correlation between the arsenic-induced apoptotic mechanism and cognitive losses is yet awaited.
Bone morphogenetic proteins (BMPs) are a group of multifunctional members of transforming growth factor (TGF)-b superfamily, and hippocampal performance seemed to be profoundly affected by BMP signaling pathway (Bonaguidi et al., 2008; Gobeske et al., 2009) . BMP2, 4, and 6 proteins are expressed in the hippocampal neurons, and their binding to type I (BMPR1A and BMPR1B) and type II (BMPR2) receptor subunits transmit signals via the phosphorylated cytoplasmic Smad proteins (Martinez et al., 2001; Mira et al., 2010; Tomizawa et al., 1995; Yousef et al., 2015; Zhang et al., 1998) . The BMP antagonist, noggin, prevents BMP from associating with its receptors and thereby inhibits BMP/Smad signaling, culminating in altered cellular functions, even within the hippocampus (Meyers et al., 2016; Mira et al., 2010) . In addition, BMP signaling has been reported as an important mechanism connecting environmental exposure with altered cognitive behavior, where noggin over-expression played a protective role (Gobeske et al., 2009; Meyers et al., 2016) . However, it remains seeing whether BMP signaling participated in hippocampal neuronal apoptosis, and if it had any correlation with arsenic-induced cognitive deficits.
Evidence suggests that a functional integration of BMP with the neurotrophin, brain-derived neurotrophic factor (BDNF), elicits down-stream signal transduction in neurons (Chaverneff and Barrett, 2009; Galter et al., 1999; Takatoh and Wang, 2012) . BMPs have also been shown to complement the trophic effects exerted by BDNF in hippocampal cultures (Nonner et al., 2001; Watanabe et al., 2016) . Increased BDNF expression promotes survival and rescues hippocampal neurons from apoptosis (Fan et al., 2015; Wan et al., 2016) . Tropomyosin-related kinase-B (TrkB) serves as the key BDNF receptor, and activated TrkB signaling decreases hippocampal neuronal apoptosis (Qi et al., 2014; Wei et al., 2014) . Although there have been a few reports suggesting a protective role of hippocampal BDNF against arsenic-induced memory impairment (Karri et al., 2016; Sun et al., 2015) , nonetheless, the effect of arsenic on BDNF/TrkB signaling and its connection with hippocampal neuronal apoptosis awaits investigation. Most importantly, an integrated link between BMP/Smad, BDNF/TrkB, hippocampal neuronal apoptosis and cognitive impairments, particularly upon arsenic exposure remains absolutely unexplored.
In this study, we hypothesized that arsenic induces hippocampal neuronal loss involving an interlinked BMP and BDNF mechanism of action. Through in vivo and in vitro studies, we first examined the effects of environmentally relevant arsenic exposure on apoptosis within matured hippocampal neurons. We screened for the BMPs and then correlated BMP/Smad signaling with hippocampal neuronal apoptosis. We assessed participation of BDNF/TrkB signaling and explored any connection between BMP/Smad and BDNF/TrkB pathways and an ultimate arsenic-induced cognitive deficit.
Antibodies
Mouse monoclonal NeuN (cat no MAB377) and rabbit polyclonal NeuN (cat no. ABN78) antibodies were obtained from Millipore (Temecula, California) . Rabbit polyclonal cleaved caspase-3 (cat no. 9664), rabbit monoclonal PARP (cat no. 9532) and rabbit monoclonal p-Smad1/5 (cat no. 9516) antibodies were purchased from Cell Signaling Technology (Danvers, Massachusetts). Rabbit polyclonal BDNF (cat no. sc-546) and rabbit polyclonal Smad1/5/8 (cat no. 6031) antibodies were purchased from Santa Cruz Biotechnology (Dallas, Texas). Rabbit polyclonal pTrkB (cat no. ab109684), TrkB (cat no. ab18987), BMP2 (cat no. ab14933), BMPR2 (cat no. ab96826) and double cortin (DCX, cat no. ab18723) antibodies were purchased from Abcam (Cambridge, Massachusetts). Mouse monoclonal b-actin (cat no. A5441) and Ki67 (cat no. P6834) antibodies, horseradishperoxide (HRP)-conjugated secondary anti-rabbit IgG (cat no. A0545) and anti-mouse IgG (cat no. A9044) were from Sigma Chemical Co. (St Louis, Missouri). Alexa FluorV R 546 goat antirabbit IgG (cat no. A11010) and Alexa FluorV R 488 goat anti-mouse IgG (cat no. A11001) were from Invitrogen (Carlsbad, California).
Animals and Treatments

Ethical Approval of Animal Experiments
Wistar rats were procured from the animal house of CSIRIndian Institute of Toxicology Research and were kept under standard 12h-light/dark cycle conditions with ad libitum chow diet and reverse osmosis (R.O.) water. For maintenance and handling of animals, strict regulations of Institutional Animal Ethics Committee were followed.
Metal Treatment in Animals
Pregnant females were daily treated with vehicle (R.O. water) or arsenic (Table 1) through oral gavage from gestation day 5 (G-05) until the pups weaned (Postnatal day 21, PND21) From PND22, pups were directly treated until postnatal day-60 (PND60) or 90 (PND90). Two concentrations of arsenic (1X and 10X) were used, where 1Â stands for the concentrations normally found in the groundwater of India (Abbas et al., 2013; Ashok et al., 2015; Rai et al., 2013) . Weight of the animals were measured, and feeding volume of the treatments ranged from 1 to 3 ml as per the weight of rats (Table 2) , keeping treatment concentration constant. Male off-springs were selected for this study over female offsprings to avoid interference of female reproductive cycle in the study.
Stereotaxic Surgery
To investigate the participation of BMP and BDNF in the apoptosis of hippocampal neurons, a BMP antagonist, noggin, and recombinant BDNF, respectively, was infused into the rat brain hippocampus through stereotactic surgery. The procedure used for stereotaxic surgery was based on previously published protocols (Ashok et al., 2015) . In brief, PND83 rats were anesthetized by intraperitoneal injection of ketamine and xylazine (60 and 20 mg/ kg body weight, respectively). The rats were placed in the stereotaxic apparatus (Stoelting Co., USA) with their hair shaved off from the skull portion, and were disinfected with betadine. An incision was made into the scalp and drilled at decided stereotaxic coordinates, 3.5 mm anterior-posterior to bregma, 62.2 mm mediolateral and 2.5 mm dorsoventral following an earlier protocol . Recombinant noggin, 1 mg in 5 ml distilled water (de Chevigny et al., 2008; Mira et al., 2010) or recombinant BDNF, 1 mg in 5 ml sterile saline (Takeshima et al., 2011; Zhang et al., 2015) were bilaterally injected at a slow rate (1 ll/min) into the hippocampus with a 10 ll Hamilton syringe, once, at PND83 in arsenic-treated rats and dissected after 7 days. The vehicle-control rats for these groups were treated with sterile distilled water (vehicle for noggin) or saline (vehicle for BDNF) that followed the same procedure.
Evaluation of Arsenic in Brain
Instrumentation. The analysis of arsenic concentration was performed in an Atomic Fluorescence Spectrophotometer (AFS) equipped with an autosampler, an assembly of hydride generator, and high-intensity hollow cathode lamp (instrument model AF-420, PG Instruments), as previously (Rai et al., 2010) . Data integration and processing was carried out in a manufacturer brand PF Win software. 50 mA main auxiliary current and 200 C of atomizer temperature were set respectively, with the scanning time of 15 s. A steady baseline was obtained under the optimized spectroscopic condition. Standard solutions (1 ml) of arsenic and sample solution (0.1 ml) were aspirated with reducer (10% sodium borohydride solution) and carrier liquid of 1.5 and 1 ml, respectively, and spectrograms were recorded by measuring the absorbance using an arsenic hollow-cathode lamp as a source.
Sample preparation and analysis. To determine arsenic level, the hippocampal tissues were harvested and snap frozen immediately by treating with liquid nitrogen and stored in À80 C freezer until analysis. At the time of the arsenic concentration estimation, each tissue samples was digested in 2 ml of concentrated HNO 3 and kept overnight at 60 C. Further, arsenic was reduced by the addition of 1 ml 10% solution (wt/v) of ascorbic acid and potassium iodide and 1 ml 10% HCl (v/v) solution in each digested sample. After 45 min, the resulting 4 ml sample solution was centrifuged for 5 min at 10 000 rpm, and 2ml supernatant solution of each sample was taken and diluted with 10% HCl solution to generate a volume of 10 ml. The concentration of arsenic in each sample was calculated from the The calibration curve was plotted by using a standard solution prepared from a stock solution (1 mg/ml). A 100 ml of stock solution was taken with 1.9 ml of 10% HCl in a 15 ml centrifuge tube, and 1 ml mixed solution of 10% ascorbic acid and potassium iodide was added. After 45 min, the reduced solution was diluted up to 10 ml with 10% HCl solution to give a concentration of 10 ng/ml. Further, calibration curve in the range of 0.5-5 ng/ml was plotted, and regression coefficient, slope and intercept were calculated. Limit of detection (LOD) and limit of quantification (LOQ) of arsenic were calculated from the equation of standard deviation of the response and the slope as mentioned in ICH guideline: LOD ¼ 3Âr/s and LOQ ¼ 10Âr/s, where r and S are the standard deviation of the response and slope of the calibration curve, respectively.
Protein extraction and western blotting
In Vivo. Protein extraction and Western blotting were performed following an earlier published protocol (Ashok et al., 2016 
Cryosectioning
Three wistar rats from 3 different litters were used for cryosectioning, based on the previously described protocol (Ashok et al., 2015; Rai et al., 2010) . In brief, PND60 and PND90 rats from control and treated groups were deeply anesthetized and rat brain was perfusion-fixed with 4% paraformaldehyde containing 0.2% picric acid. The brain was isolated carefully and cryoprotected by using sucrose gradients (10%, 20%, and 30%) and embedded in optimal cutting temperature compound (Miles Inc., Elkhart, Indiana) at low temperature (À20 C) inside the cryomicrotome (Microm HM 520, Labcon, Germany). Ten-mm thick coronal sections of the hippocampus were taken on (3-Aminopropyl) triethoxy-silane coated slides and stored at À20 C.
Nissl's staining
In Vivo. Damage in the hippocampal neurons of PND60 and PND90 rat brain was examined through Nissl staining using previously described protocol . In brief, 10-mm thick hippocampal cryosections from each treatment group were air dried and immersed in chloroform:alcohol (1:1) for 1-2 h followed by rehydration in 95%-100% alcohol. The sections were then stained with 0.1% cresyl violet solution for 5-10 min at 50 C, rinsed quickly with distilled water and dehydrated with 75%-100% ethyl alcohol for 2-10 min. Sections were cleared in Xylene and mounted with DPX. Stained sections were visualized, and images were taken using Nikon Eclipse E600 microscope (Tallahassee, Florida). Images were imported into Image-J 1.48v software, and % of surviving neurons were quantified using 5 randomly selected areas in the hippocampal sections. Neurons with intact morphology and dark stained were considered as surviving neurons . Calculation of surviving neurons were as % surviving neurons ¼ 100 Â (count of surviving neurons/total count of neurons).
Immunohistochemistry
For detecting expression of cleaved caspase-3, BMP2, p-Smad1/ 5, BMPR2, BDNF and p-TrkB in NeuN-expressing cells, fluorescence immunohistochemistry was performed using previously described protocol (Ashok et al., 2015; Rai et al., 2010) . To examine neurogenesis, Ki67 and DCX were co-immunolabeled. In brief, 10-mm thick coronal sections of the hippocampus were subjected to antigen retrieval in the citrate buffer (pH 6.0). The slides were then washed twice in PBS followed by blocking for 1 h using 3% BSA in PBS. The sections were then probed with anti-mouse NeuN and co-labeled with anti-rabbit cleaved caspase-3 (c-Cas3), BMP-2, p-Smad1/5, BMPR2, BDNF, and pTrkB (1:100 dilutions in PBS), or anti-rabbit DCX co-labeled with anti-mouse Ki67, overnight at 4 C. Slides were rinsed with 0. 
TUNEL Assay
TUNEL assay was performed for in situ detection of apoptosis in the hippocampus of the PND60 and PND90 rat brain, as described earlier (Rai et al., 2010) . In brief, 10-mm thick coronal sections were air dried and washed with 0.1 M PBS and antigen-retrieved with citrate buffer. The sections were incubated with fluorescein-labeled dUTP in the presence of TdT at 37 C for 2 h, washed thrice in PBS and blocked in 3%BSA in PBS for 1 h. The sections were then immunostained with anti-rabbit NeuN (1:200 dilution in PBS) antibody and kept overnight at 4 C. Sections were then washed, incubated with Alexa Fluor 546 goat anti-rabbit antibodies (1:400 dilutions in PBS) for 1-2 h at room temperature, washed in PBS and counterstained with Hoechst 33258 (0.2 mM) for 5 min. Following this, the sections were mounted in Vectashield mounting medium and visualized with a fluorescence microscope (Nikon Instech Co. Ltd., Kawasaki, Kanagawa, Japan). Images were captured and imported into Image-J 1.48v for image analysis where NeuN and TUNEL-positive neurons were counted in 5 randomly selected areas within the hippocampal region. Cells were counted manually using a cell counter protocol in ImageJ, as ImageJ ! Plugins ! Analyze ! Cell counter. The apoptotic index was expressed as the number of TUNEL-positive cells per 100 Hoechst-stained nuclei.
Cell Culture and Treatments
Rat primary hippocampal neuron culture. Pregnant Wistar rats were killed by cervical dislocation and embryos were removed from embryonic-16 (E16) as described earlier (Ray et al., 1993) . Hippocampal region within the brain of E16 rats was dissected out in HBSS. The outermost thin layer of the meninges was removed, followed by mechanical digestion in serum free neurobasal media. The suspension was again digested by using 0.05% trypsin-EDTA and incubated for 15 min at 37 C in humidified CO 2 incubator at 37 C with 5% CO 2 . The effect of trypsin was neutralized with trypsin inhibitor, and non-cellular debris was removed by briefly sucking with a dispenser. The remaining suspension was centrifuged at 1500 rpm for 10 min. The pellet was suspended in neurobasal containing N2 supplement (1%), B-27 supplement (2%), 2 mM L-glutamine, penicillin (100 units/ml) and streptomycin (100 lg/ml). 1.5Â10 6 cells/well were plated on poly-L-lysine-coated 6-well culture plates and grown in humidified CO 2 incubator at 37 C with 5% CO 2 .
Neurons were confirmed on seeing cell morphology and immunostaining with the NeuN antibody and counterstaining with Hoechst 33258.
Neuron treatments
Primary hippocampal neurons were treated with arsenic in the form of sodium arsenite (NaAsO 2 ) at different concentrations ranging from 0 to 10 mM for different time points (0, 6, 12, and 18 h).
The values covered the range of metal concentrations reaching the brain (Table 3) , detected upon treating rats with environmentally relevant metal concentrations (refer to in vivo treatments). To study the involvement of BMP, BDNF and TrkB signaling, primary neurons were pre-treated for 1 h with noggin (100 ng/ml; Mira et al., 2010) , recombinant BDNF [100 ng/ml; Almeida et al., 2005 or K252a (TrkB receptor inhibitor, 200 nM); Wang et al., 2008] , respectively, and then co-treated with arsenic for 12 h.
MTT assay
MTT assay was performed to determine the viability of primary neurons following arsenic treatment, using the optimized protocol (Rai et al., 2010) . After arsenic treatment, neurons were then incubated for 4 h with MTT reagent (10.4 mg/ml) and cell viability was determined following a previously published protocol (Sanders et al., 2010) . Absorbance was measured at 595 nm, and with a background subtraction at 655 nm using a Microplate reader (Tecan, infinite 200 PRO, Switzerland) . Experiments were performed thrice with 3 replicates each time. Relative neuronal cell viability (%) was expressed as a percentage of viable neurons following arsenic treatment relative to the 0 mM.
Neuronal count and morphology
To examine the effect of arsenic on neuronal count and morphology, primary hippocampal neurons were plated onto poly-L-lysine-coated chamber slides. On fifth day, the neurons were treated with 0-5 lM of arsenic for 18 h and then visualized under an inverted microscope (Nikon Instech Co. Ltd) using 60Â objective. Images were captured using NIS-Elements microscope imaging software (Nikon Instech Co. Ltd.). Neuronal cell number and perimeter were determined manually using ImageJ software, and the number of dendritic branches/neuron and dendritic length were calculated by Neuron-J plugin of ImageJ software.
Protein extraction and western blotting (in vitro)
Primary hippocampal neurons were first lysed with CelLytic lysis reagent along with protease inhibitor cocktail and 1 mM dithiothreitol, and Western blotting carried out as previously described (Agarwal et al., 2015) . For determining the expression levels of phosphorylated proteins, 1 mM sodium orthovanadate and 25 mM sodium fluoride was also added in CelLytic Lysis reagent. The cells were scraped and collected in microcentrifuge tubes followed by sonication to rupture the cell. The lysate was centrifuged at 12 000 rpm for 30 min at 4 C, and then basic method for Western blotting was the same as done for samples isolated from in vivo experiments. Primary antibodies (1:1000 dilution) of NeuN, cleaved caspase-3, PARP, BMP2, p-Smad1/5, Smad1/5, BMPR2, BDNF, p-TrkB, and TrkB were used for study. For loading control, b-actin with 1:10 000 dilution was used. The membranes were then washed 3 times with TBST and incubated for 2 h with HRPconjugated secondary anti-rabbit IgG (1:2000) and anti-mouse IgG (1:2000 or 1:20 000) antibodies prepared in TBST. The protein bands were detected using Immobilon Western Chemiluminescent HRP Substrate and relative expression quantified.
Real-time PCR (quantitative PCR, qPCR)
The cultured neuronal cells were treated with arsenic in neurobasal medium. After 18 h of treatment, the media were aspirated out, and RNA was isolated through TRIzol reagent using a standardized protocol (Bandyopadhyay et al., 2006) . Isolated RNA was dissolved in RNase DNase-free water and was quantified before complementary DNA (cDNA) synthesis. A 5-mg of total RNA was used to prepare cDNA by using reverse transcription PCR (Superscript III, Life Technologies) according to manufacturer's protocol. qPCR was then performed using SYBR green dye. Optimum primer pairs for BMP2, BMP4, BMP6, BDNF and internal housekeeping control gene, glyceraldehydes 3-phosphate dehydrogenase (GAPDH) ( ; where delta cycle threshold (DC T ) denoted a difference in C T values between the target gene and GAPDH, and DDC T signified the differences in the DC T value of treated sets compared to control. Results obtained were confirmed by running qPCR products on 2% agarose gel.
Immunocytochemistry
Immunocytochemistry of primary hippocampal neurons was performed based on a previously described protocol with slight modifications . In brief, primary hippocampal neurons were plated onto poly-L-lysine-coated chamber slides. On the 5th day, cells were treated with arsenic. The cells were then fixed using 4% PFA for 20 min, washed with PBS, followed by permeabilization in methanol at À20 C for 30 min. Cells were washed thrice with PBS and blocked with 3% blocking serum, BSA, and then incubated overnight with primary mouse antiNeuN (1:400) and rabbit anti-BMP-2, BMPR2 or p-Smad1/5 (1:200) antibodies. Cells were washed with PBS, followed by incubation with Alexa Fluor 488 anti-mouse (1:800) and Alexa Flour antirabbit (1:400) antibodies for 1-2 h. The cells were washed in PBS, dried, mounted in DAPI containing Vectashield mounting medium (Vector Laboratories, Burlingame, California) and visualized through an fluorescence microscope (Nikon Instech Co. Ltd., Kawasaki, Kanagawa, Japan) using 60Â objective. Images were captured using NIS-Elements microscope imaging software (Nikon Instech Co. Ltd., Kawasaki, Kanagawa, Japan).
siRNA transfection BMP2 siRNA was transfected in primary hippocampal neurons using Lipofectamine as per the manufacturer's protocol. In brief, non-targeting siRNA (NT-siRNA) (5 nM) or BMP2 siRNA (siRNA ID-s131268, Gene ID: 29373) (5 nM) and lipofectamine reagent were suspended in the neurobasal medium for 30 min at 37 C. The complex formed was then treated to the primary hippocampal neurons. BMP2 silencing in primary neurons was confirmed through Western blotting. The NT-siRNA was selected as a control for BMP2-siRNA.
Behavioral study:
Passive avoidance test. Learning and memory performances were assessed by providing an aversive stimulus (footshock) as described earlier (Maurya et al., 2016) . Rats were placed in a light compartment of a shuttle box (Techno, India), which was separated from the dark compartment by a gate. Rats were allowed to acclimatize in the light compartment for 30 s, and then allowed to enter the dark compartment where the rats received a foot shock of 0.5 mA for 10 s, and this trial was considered as acquisition trial (aq.). On the following days, retention (R) was tested in consecutive trials at 24 h (R1), 48 h (R2), and 72 h (R3) of acquisition trial. Retention trials were shock-free, and 300 s were given for each trial. Time taken (in seconds) by the rats to shift from light compartment to dark compartment was recorded as transfer latency time (TLT). Learning was assessed upon the basis of increased TLT during retention trials as compared to acquisition trial.
Y-Maze test. Memory assessment in the rats was carried out as previously described (Rai et al., 2010) . Briefly, Y-Maze apparatus had a Y-shaped maze with 3 arms joined at the middle, where one arm had a 15-W light bulb and without foot shock (safe arm), while other two arms were without light and had electric footshock of 1-5 mA (unsafe arm). The safe and unsafe arms were randomly shifted during the training period. Thirty trials of training period were given to every rat, for which running towards the unsafe arm (dark arm) was counted as an error (E). Retention (memory) test was performed at 24 h, 48 h, and 7th day of the posttraining period, and it was used to calculate % of saving memory, expressed as: % saving memory ¼ (E training ÀE test ) Â 100/E training .
Statistics
Statistical analyses were performed using GraphPad PRISM software (GraphPad software, Inc., SanDiego, California). For comparison between 2 groups of independent samples, Student t test with 2-tailed distribution was carried out. For comparison between more than 2 groups, one-way analysis of variance followed by the Tukey's post-hoc multiple comparisons test was performed.
RESULTS
Arsenic Induces Dose-Dependent Hippocampal Neuronal Apoptosis and Neuronal Loss Chronic arsenic exposure is known to induce cognitive deficits in rats (Jing et al., 2012; Ramos-Chavez et al., 2015; Tyler and Allan, 2014) . Hippocampal neurons play an important role in maintaining cognitive performance (Barnes, 1988; CouillardDespres et al., 2011) , and hence we investigated the effect of arsenic on hippocampal neurons. We fed rats with environmentally relevant doses of arsenic (1Â and 10Â) from G-05 until PND60 and PND90, and examined expression levels of matured neuronal marker, NeuN, within the hippocampus. We detected a dose and time-dependent reduction in NeuN levels by arsenic ( Figure 1A ). Nissl staining supported the arsenic-induced neuronal loss (Supplementary material 1) . To identify if apoptosis could be responsible for this arsenic-mediated attenuation in NeuN, we measured cleaved caspase-3 expression levels in NeuN-expressing cells within the hippocampus. We detected an increased dose and time-dependent expression of cleaved caspase-3 ( Figure 1B ) indicating enhanced hippocampal neuronal apoptosis following arsenic treatment. Increased number of TUNEL-positivity validated increased apoptosis within the hippocampal neurons ( Figure 1C ; Supplementary material 2). We verified the effects of arsenic, in vitro, in the rat primary hippocampal neurons. For deciding the in vitro treatments, we first assessed arsenic levels in the hippocampus at PND60 and PND90 following 1Â and 10Â dose of arsenic treatments in the rats. Supporting earlier studies (Rai et al., 2010; Yadav et al., 2009) we observed dose-dependent increased arsenic levels in the hippocampus (Table 3) . We then treated primary hippocampal neurons with arsenic at a range of 0.001-10 lM, which comprised levels detected in the rat brain hippocampus (refer to with arsenic at indicated doses for 6, 12, or 18 h, and cell viability was determined by MTT assay. Line graph shows % of neuronal cell viability, and data represent mean 6 SE of 3 independent experiments in triplicates. ***P < .001, **P < .01, and *P < .05 compared with 0 lM. B-D, Representative western blot and densitometry show modulated cleaved caspase-3 (B), cleaved-PARP/PARP (C) and NeuN (D) expressions normalized with b-actin at indicated arsenic doses in rat primary hippocampal neurons. Data represent mean 6 SE of 3 to 5 independent experiments. ***P < .001, **P < .01, and *P < .05 compared with 0 lM or as indicated. E, Bright-field photomicrograph (60Â) and bar diagram showing neuronal count, number of dendrites/neuron, dendritic length and perimeter of the neurons following arsenic-treatment for 18 h in rat primary neurons. Data represent means 6 SE of 4 independent experiments. ***P < .001, **P < .01, and *P < .05 compared with 0 lM or as indicated. Table 3 ). We carried out MTT assay, and detected that arsenic induced a dose and time-dependent significant loss in neuronal cell viability (Figure 2A ). Corroborating our in vivo observation, we detected an arsenic-mediated increased apoptosis, marked by enhanced dose-dependent cleaved caspase-3 ( Figure 2B ) and cleaved-PARP ( Figure 2C ) expression levels in the arsenictreated hippocampal neurons. We verified dose-dependent reduction of NeuN levels in arsenic-treated primary hippocampal neurons through Western blotting as well ( Figure 2D ). Hippocampal neuronal loss associates with neuritic dystrophy Pike et al., 1992) , and hence we examined the effect of arsenic on morphology of primary hippocampal neurons. We detected reduction in the neuronal count and identified a decrease in dendritic branches, dendritic length, and perimeter of neurons ( Figure 2E ). Thus, our data indicate an increased apoptosis and damage to hippocampal neuronal morphology following environmentally relevant doses of arsenic exposure.
Arsenic Induces BMP2-Dependent Apoptosis in the Hippocampal Neurons
We explored the mechanism stimulating arsenic-mediated apoptosis within the hippocampal neurons. BMPs are known to have a neuron specific neuroprotective role (Luan et al., 2015; Pei et al., 2013) , and conversely an up-regulated BMP signaling has been proved to associate with cerebral damage (Martinez et al., 2001; Pal et al., 2016) . We examined if arsenic had any effect on the BMP signaling pathway of hippocampal neurons. We measured mRNA levels of the key BMP ligands found in hippocampal neurons, viz. BMP2, BMP4 and BMP6 (Apel et al., 2009; Bond et al., 2014; Crews et al., 2010) , and detected an arsenic-mediated dosedependent enhanced expression of BMP2 mRNA ( Figure 3A ). BMP4 and BMP6 were relatively very less affected (data not shown). We verified the dose-dependent increased BMP2 protein levels through Western blot and immunocytochemistry in primary hippocampal neurons (Figs. 3B and C). We further examined the effects, in vivo, through immunohistochemistry and identified an arsenic-mediated dose-dependent increased BMP2 expression in hippocampal NeuN-expressing cells within the rat brain ( Figure 3D ). To assess whether enhanced BMP2 participated in neuronal apoptosis, we examined the effect of BMP2-siRNA in arsenic-treated primary hippocampal neurons. BMP2-siRNA suppressed arsenic-induced BMP2 ( Figure 3E ), cleaved caspase-3 ( Figure 3F ) and cleaved-PARP/PARP ( Figure 3G ) levels. In addition, we found that BMP2-siRNA inhibited arsenic-mediated reduction in NeuN levels ( Figure 3H ). Thus, our results prove that arsenic-induced apoptosis and loss in hippocampal neurons could be BMP2-dependent.
Arsenic Stimulates BMP2/Smad-Dependent Apoptosis and Hippocampal Neuronal Loss
BMPs transduce their signals through type I and type II receptors and downstream Smad signaling, marked by its phosphorylation (Katagiri and Watabe, 2016) , and hence we examined the effect of arsenic on BMP receptors and p-Smad. We observed an up-regulated expression of BMPR2 through western blot ( Figure  4A ) and immunocytochemistry ( Figure 4B ) in primary hippocampal neurons. The effect of arsenic on BMPR1 expression was non-significant (Supplementary material 3). We then examined p-Smad 1/5 levels, and observed its arsenic-mediated increased expression through both Western blotting and immunocytochemistry ( ( Figure 4E ) and p-Smad 1/5 ( Figure 4F ), in vivo, in hippocampal neurons of arsenic-treated rats. To understand whether this BMP2/Smad signaling participated in neuronal apoptosis, we co-treated arsenic with BMP2 antagonist, noggin, in the primary hippocampal neurons. We found that noggin not only attenuated arsenic-induced p-Smad 1/5 ( Figure 5A ), but also suppressed cleaved caspase-3 ( Figure 5B ) and cleaved-PARP/PARP levels ( Figure 5C ), proving the participation of increased BMP2/Smad signaling in hippocampal neuronal apoptosis. Noggin co-treatment restored NeuN levels in the arsenic-treated neurons as well ( Figure 5D ). For in vivo examination of BMP2/Smad participation in hippocampal neuronal apoptosis, we infused noggin into the hippocampus of arsenictreated rats. We observed a noggin-mediated attenuation in pSmad 1/5 ( Figure 5E ), and also detected decreased number of TUNEL-positive neurons associated with increased NeuN expression in the arsenic-treated rat brain hippocampus ( Figure 5F ). Thus, our results proved that arsenic enhances BMP2/Smaddependent increased apoptosis and decreased NeuN levels within the rat brain hippocampal neurons.
Arsenic-Induced BMP2/Smad Attenuates BDNF, Which Induces Apoptosis of Hippocampal Neurons
We then explored the effect of arsenic on the hippocampal neuronal survival pathway, hypothesizing involvement of the neurotrophin, BDNF, which prevents neuronal apoptosis and protects against hippocampal damage (Liang et al., 2015; Qi et al., 2014) . Through qPCR, we detected that arsenic caused a dose-dependent reduction in BDNF mRNA levels of hippocampal neurons ( Figure  6A ). We verified arsenic-mediated BDNF reduction through Western blotting ( Figure 6B ). We further observed that co-treating arsenic-treated neurons with recombinant BDNF reduced arsenicinduced cleaved caspase-3 ( Figure 6C ) and cleaved-PARP/PARP ( Figure 6D ) levels, indicating BDNF-mediated decrease in hippocampal neuronal apoptosis. For in vivo verification, we infused recombinant BDNF into the rat brain hippocampus. We detected a decrease in TUNEL-positive hippocampal neurons, along with an increase in NeuN expression following BDNF treatments in arsenic-treated rats ( Figure 6E ).
To identify whether BDNF and BMP pathways could be linked, we co-treated arsenic with noggin or recombinant BDNF in the primary hippocampal neurons, and examined the BDNF and BMP2 levels, respectively. We detected that noggin cotreatment restored BDNF ( Figure 6F ), while recombinant BDNF failed to affect BMP2 levels ( Figure 6G ), proving an increased BMP2-dependent attenuated BDNF expression in the arsenictreated hippocampal neurons. For in vivo verification, we infused noggin into the rat brain hippocampus. We detected a noggin-mediated increase in BDNF expression in hippocampal neurons of the arsenic-treated rat brain ( Figure 6H ). Thus, our results proved that arsenic promotes BMP2/Smad signaling, which reduces BDNF, thereby enhancing apoptosis within hippocampal neurons.
Arsenic-Induced BMP2/Smad Essentially Requires Attenuated BDNF/TrkB Signaling for Hippocampal Neuronal Apoptosis We explored BDNF signaling, and detected an arsenic-mediated inactivation of its key mediator, TrkB, marked by reduced dosedependent p-TrkB levels ( Figure 7A ). We found that recombinant BDNF co-treatment restored p-TrkB levels in arsenic-treated neurons ( Figure 7B ), indicating an attenuated BDNF-dependent reduced TrkB signaling following arsenic treatment. To correlate with BMP2/Smad, we examined the effects of noggin on pTrkB. We detected a noggin-mediated restoration in the p-TrkB Figure 3 . Arsenic induces BMP2 promoting apoptosis in the hippocampal neurons. Rat primary hippocampal neurons were treated with arsenic at indicated doses for 12 h. A, qPCR of BMP2 was performed, and relative mRNA levels of BMP2 were normalized against housekeeping gene GAPDH following arsenic treatment. Data represent means 6 SE of 3 independent experiments and in triplicates each for qPCR. ***P < .001, **P < .01, and *P < .05 compared with 0 lM. B, Rat primary hippocampal neurons were immunoblotted for BMP2 (45 kDa) and b-actin (42 kDa). Representative Western blot and densitometry show increased BMP2 expression levels normalized with b-actin following arsenic treatment in primary hippocampal neurons. Data represent means 6 SE of 3 independent experiments. ***P < .001, **P < .01, and *P < .05 experiments. ***P < .001 and *P < .05 compared with V þ NT siRNA or as indicated. b-actin. Data represent means 6 SE of 3 independent experiments. ***P < .001, **P < .01 and *P < .05 compared with 0 lM or as indicated. E-F, Ten-mm-thick cryostat coronal sections of the hippocampus from PND90 rats following indicated treatments were co-immunostained with BMPR2 and NeuN antibodies and counterstained with Hoechst. Representative photomicrographs (10Â magnification) and bar diagram show increased BMPR2 (E) and p-Smad1/5 (F) and decreased NeuN (E-F) immunofluorescence intensity against nuclear-Hoechst in the hippocampal sections of the arsenic-treated group as compared to the vehicle. Data are representatives of 3 rats from 3 different litters. Bar diagrams represent means 6 SE. ***P < .001 and **P < .01 designate significant difference compared with the vehicle (V). levels in the rat hippocampal neurons ( Figure 7C ). To verify our in vitro observations in vivo, we co-treated arsenic with recombinant BDNF in the rats. We detected that BDNF co-treatment restored p-TrkB levels in the hippocampus of arsenic-treated rats ( Figure 7D ), validating the attenuated BDNF-dependent reduced TrkB signaling following arsenic treatment. We additionally detected that co-treatment with noggin restored p-TrkB levels in the hippocampus of arsenic-treated rats ( Figure 7E ) proving a BMP2-dependent attenuation of BDNF/TrkB signaling in the hippocampal neurons within the arsenic-treated rat brain. To understand whether BMP2-mediated neuronal apoptosis was dependent on the attenuated BDNF/TrkB, we inhibited BDNF/TrkB signaling using K252a in the noggin þ arsenic-treated hippocampal neurons. We detected that noggin failed to suppress arsenic-induced cleaved caspase-3 ( Figure 7F ) and cleaved-PARP/ PARP ( Figure 7G ) in K252a co-treated neurons. We also detected that noggin failed to inhibit arsenic-induced neuronal loss in the presence of K252a (Figure 7H ), proving that decreased BDNF/TrkB signaling, downstream of increased BMP2/Smad signaling, was indeed responsible for arsenic-induced apoptosis and hippocampal neuronal loss.
Noggin Restores Cognitive Performance in Arsenic-Treated Rats
We then correlated our observations with cognitive performances, focusing upon BMP2/Smad signaling, which here served as the up-stream pivotal inducer of arsenic-mediated apoptosis and neuronal loss within the hippocampus. We examined the effects of noggin on learning-memory performances, through passive avoidance and Y-Maze tests, in arsenic-treated rats. We detected that in passive avoidance test, arsenic-treated rats showed a decreased enhancement in TLT of retention trials compared with acquisition trials, and co-treatment with noggin inhibited the change ( Figure 8A ). Likewise arsenic-treated rats demonstrated increased errors during training (learning) and reduced % saving memory at 24 h, 48 h, and 7th day post-learning, which could be inhibited by noggin ( Figure 8B ). Thus, our data prove that (100 ng/ml) followed by vehicle or arsenic treatments (5 and 10 mM) for 12 h. Representative Western blot and densitometry show arsenic-mediated changes in pSmad1/5 relative smad1/5 (A), cleaved caspase-3 (B), cleaved-PARP/PARP (C), and NeuN (D) expression levels normalized with b-actin and reversal through noggin supplementation. Data represent means 6 SE of 3 independent experiments. ***P < .001 and *P < .05 compared with vehicle (V) or as indicated. E, Hippocampal tissues from vehicle, arsenic (10Â) and arsenic þ noggin-treated rats were immunoblotted for p-Smad1/5 (60 kDa) and b-actin (42 kDa) at PND90. Representative western blot and densitometry show arsenic-mediated increase in p-Smad1/5 expression levels normalized with b-actin and its reversal through noggin supplementation. Data represent means 6 SE of 3 independent experiments. ***P < .001 and *P < .05 compared with vehicle or as indicated. F, Representative photomicrographs (10Â magnification) and bar diagram show increased TUNEL reactivity in NeuN-labeled cells against nuclear-Hoechst in the arsenic-treated group and its suppression in arsenic þ noggin group in the hippocampal sections. Data are representatives of 3 rats from 3 different litters. Bar diagram represents % apoptotic index of neurons. ***P < .001 and *P < .05 compared with vehicle or as indicated. Figure 6 . Arsenic-induced BMP2 suppresses BDNF expression, which contributes to apoptosis of hippocampal neurons. A, Rat primary hippocampal neurons were treated with arsenic at indicated doses for 12 h. qPCR of BDNF was performed, and BDNF mRNA levels were normalized against housekeeping gene GAPDH following arsenic treatment. Data represent means 6 SE of 3 independent experiments in triplicates. ***P < .001, **P < .01, and *P < .05 compared with 0 lM or as indicated. B, Representative Western blot and densitometry show reduced BDNF levels normalized with b-actin in arsenic-treated primary hippocampal neurons. Data represent means 6 SE of 3 independent experiments. ***P < .001, **P < .01, and *P < .05 compared with 0 lM or as indicated. C, D, and G, Rat primary hippocampal neurons were supplemented with BDNF (100 ng/ml) followed by vehicle or arsenic (5 and 10 mM) treatments for 12 h. Representative Western blot and densitometry show reduced levels of cleaved caspase-3 (C) and cleaved-PARP/PARP ratio (D) and unchanged BMP2 levels (G) normalized with b-actin following BDNF supplementation in the arsenictreated hippocampal neurons. Data represent means 6 SE of 3 independent experiments. ***P < .001 and **P < .01 compared with vehicle (V) or as indicated. E, Representative photomicrographs (10Â magnification) and the bar diagram show increased TUNEL reactivity in NeuN-labeled cells against nuclear-Hoechst in arsenictreated group and its suppression in arsenic þ BDNF group in cryostat sections of the hippocampus. F, Rat primary hippocampal neurons were supplemented with noggin (100 ng/ml) followed by vehicle or arsenic (5 and 10 mM) treatments for 12 h. Representative Western blot and densitometry show restored BDNF levels normalized with b-actin following noggin supplementation in arsenic-treated hippocampal neurons. Data represent means 6 SE of 3 independent experiments. ***P < .001 and increased BMP2/Smad signaling plays an important role in promoting arsenic-mediated cognitive deficits.
DISCUSSION
This study furnishes the first evidence that environmentally relevant arsenic exposure triggers hippocampal neuronal apoptosis via an integrated BMP and BDNF signaling pathway, resulting in learning-memory impairment. We specifically identified that arsenic-mediated increase in BMP2/Smad signaling suppressed BDNF/TrkB neuronal survival pathway within the hippocampus. We additionally found that a BMP antagonist could oppose the effect of arsenic, attenuating hippocampal neuronal apoptosis and resultant cognitive decline (Figure 9 ).
Through both in vivo and in vitro studies, we first validated a dose-and time-dependent neuronal loss following environmentally relevant arsenic exposure. We correlated the same with increased neuronal apoptosis. An earlier study showed decreased packing density of cells, substantiated through increased TUNEL staining, within the arsenic-treated rat brain hippocampus (Kaler et al., 2013) . In this study, we extrapolated the observation, demonstrating augmented TUNEL positivity, and cleaved caspase-3 expression within the NeuN-stained cells, clearly portraying apoptosis of the hippocampal neurons. We confirmed the same through explicit in vitro studies, and also observed neuritic dystrophy characterized by marked changes in the morphology of arsenic-treated cultured hippocampal neurons. Earlier studies revealed that arsenic could impair neurite elongation in immortalized cell lines Frankel et al., 2009) . Decreased neuronal outgrowth has also been reported to have a distinct link with cortical neuronal cell death following arsenic exposure (Aung et al., 2016; Maekawa et al., 2013) . This study added to this concept, showing an alteration in the morphology of arsenic-treated hippocampal neurons. Nonetheless, unlike the earlier study showing an unchanged dendritic spine density of cortical neurons (Aung et al., 2016) , the present study reveals a reduction in dendritic count in the arsenic-treated hippocamplal neurons, proving the brain region-based diverse impact of arsenic on neurons. In addition, our in vitro and in vivo data depicting reduced NeuN expression offered a precise validation of the detrimental impact of arsenic upon the hippocampal neurons.
We established increased BMP, particularly BMP2 signaling, as a key causative mechanism triggering arsenic-induced hippocampal neuronal damage. Until now, there have been hardly any studies associating harmful effects of arsenic, or any known heavy-metal toxicants with cerebral BMP signaling. Moreover, although a link between arsenic exposure and BMP pathway was indicated in the differentiation of osteoblast, keratinocyte, and renal cells (Phillips et al., 2013; Tokar et al., 2013; Wu et al., 2014) , a correlation with apoptosis remained unknown. Hence, our findings on arsenic-induced neuronal apoptosis appear extremely novel, and may help unraveling vital concepts linking BMP with cellular apoptosis, particularly upon environmental toxicant(s) exposures.
Several contradictory results relating BMP with neuronal apoptosis have emerged. Whereas some emphasize upon the strong neurotrophic effects of the ligand (Barneda-Zahonero et al., 2009; Beckham et al., 2009; Luan et al., 2015; Pei et al., 2013; Yabe et al., 2002) , few suggest its contribution in enhanced neuronal apoptosis (Mabie et al., 1999; Pal et al., 2016) . We propose that variations in the participating BMP isoforms may explain the discrepant behavior. While the protective impact mainly related to BMP6 and BMP7 ligands (Barneda-Zahonero et al., 2009; Beckham et al.,2009; Luan et al., 2015; Pei et al., 2013; Yabe et al.,2002) , contrarily, supporting the results of the current study, BMP2 ligand demonstrated a stronger association with neuronal apoptosis (Martinez et al., 2001; Pal et al., 2016) . A BMPindependent apoptosis of hippocampal neurons has also been hinted (Berkowicz et al., 2016) ; however, the observations were more relevant for embryonic and developmental stages, unlike the findings of the present study at adulthood. Thus, our results together with the earlier ones provide an intriguing clue that BMP isoforms bear disparate effects on neurocellular properties, and their mode of functioning during neurodevelopment varies from that at maturity. Nonetheless, BMP ligand-dependent differential effects on neurons demand in-depth validation to arrive at a perfect conclusion.
Our data proved that BMPR2 served as a major participant in arsenic-induced neuronal damage, and the effect on BMPR1 was insignificant. This seemed to sustain the concept of an increased BMPR2 expression, above BMPR1, upon hippocampal injury in situations like global cerebral ischemia and mild head trauma (Charytoniuk et al., 2000; Lewen et al., 1997) . The impact also extended to the retina, where BMP2 and BMP4 via BMPR2 functioned as negative growth regulators under pathogenic conditions (Mathura et al., 2000) . The studies hypothesized that these BMPR2-mediated effects may influence synaptic plasticity and repair (Charytoniuk et al., 2000; Lewen, et al., 1997) , concluding upon prominent involvement of the receptor in pathophysiological responses following CNS injury. Thus, from this study, a significant participation of BMPR2 in controlling hippocampal tissue repair and maintenance may be proposed, especially following arsenic exposure. We found that as a fallout of arsenic-induced BMPR2 expression, increased Smad signaling performed as the pivotal regulator for hippocampal neuronal loss. BMP/Smad signaling has been proved to increase with age inhibiting hippocampal neurogenesis, and ablation of this signaling pathway rescued neurogenesis (Meyers et al., 2016; Yousef et al., 2015) . Incorporating this concept in this study, it may be stated that arsenic via increased BMP/Smad signaling accelerates the aging process of hippocampal neurons. Apoptosis being one of the crucial steps controlling neurogenesis (Ryu et al., 2016) , our data may even help speculating that arsenic attenuates hipocampal neurogenesis via BMP/Smaddependent increased apoptosis. The exacerbated neuronal apoptosis and aging could as well be responsible for an ultimate neurodegeneration, as supported by studies showing Abinduced BMP/Smad signaling and an eventual loss of hippocampal neurogenesis in the Alzheimer's disease (AD) brain. The ability of arsenic to induce AD-like pathology (Chin-Chan et al., 2015; Tyler and Allan, 2014) provided a stronger support to this concept.
Our data demonstrated that the protective role of noggin against arsenic-induced hippocampal neuronal loss appear very promising. Increased endogenous and exogenously-treated ized with b-actin, in the arsenic-treated groups. ***P < .001, **P < .01, and *P < .05 compared with 0 mM or as indicated. B and C, Rat primary hippocampal neurons were supplemented with BDNF (100 ng/ml) (B) or noggin (100 ng/ml) (C) followed by vehicle or arsenic (5 and 10 mM) treatments for 12 h. Representative Western blot and densitometry show restoration in p-TrkB relative to TrkB, normalized with b-actin, following BDNF or noggin supplementation in arsenic-treated hippocampal neurons. ***P < .001 and *P < .05 compared with V or as indicated. D, Hippocampal tissues from vehicle, arsenic (10Â) and arsenic þ BDNF-treated rats were immunoblotted for p-TrkB (91 kDa) and b-actin (42 kDa) at P-90. Representative Western blot and densitometry show arsenic-mediated decrease in p-TrkB expression levels normalized with b-actin and its reversal through BDNF supplementation. Data represent means 6 SE of 3 independent experiments. ***P < .001 and *P < .05 compared with vehicle or as indicated. E, Ten-mm-thick cryostat coronal sections of the hippocampus from PND90 rats following indicated treatments were co-immunostained with p-TrkB and NeuN antibodies and counterstained with Hoechst. Representative photomicrograph (10Â magnification) and bar diagram show reduced pTrkB and NeuN noggin, alone and in combination with related growth factors, are known to promote hippocampal neurogenesis in the adult rodent brain (Bond et al., 2014; Brooker et al., 2017; Mira et al., 2010; Tang et al., 2009) . A study also demonstrated up-regulated endogenous noggin levels alongside the anti-apoptotic cell markers in reduced hippocampal neurodegeneration (Corvino et al., 2012) . Nonetheless, although exogenous noggin treatment proved to suppress cerebral apoptosis in ischemia (Guan et al., 2013; Lu et al., 2016) , intraventricular hemorrhage (Dummula et al., 2011) , etc., a link between hippocampal noggin infusion and hippocampal neuronal apoptosis remained unexplored. The current study ably fills up the gap by proving an attenuation in neuronal apoptosis via stereotactic infusion of noggin within the hippocampus. Thus, our findings helped inferring that the noggin-mediated restoration of hippocampal neurogenesis reported in AD (Tang et al., 2009 ) may distinctively result Figure 7 . Continued immunofluorescence intensity against nuclear-Hoechst in the arsenic group and their restoration in arsenic þ noggin group. Sections are representatives of 3 rats from 3 different litters. ***P < .001 and *P < .05 compared with V or as indicated. F-H, Rat primary hippocampal neurons were treated with noggin (100 ng/ml) and noggin (100 ng/ml)þTrkB inhibitor (K252a, 200 nM) followed by arsenic (5 mM) treatment for 12 h. Representative Western blot and densitometry show decreased cleaved caspase-3 (F) and cleaved-PARP/PARP ratio (G) and increased NeuN (H) relative to b-actin in arsenic þ noggin group, while K252a co-treatment with arsenic þ noggin failed to alter their levels. Data represent means 6 SE of 3 independent experiments. ***P < .001 and *P < .05 compared with vehicle (V) or as indicated. Figure 8 . Noggin improves learning memory performance in arsenic-treated rats. To assess cognitive function, passive avoidance and Y-Maze tests were performed in vehicle, arsenic and arsenic þ noggin-treated PND90 rats. A, Representative bar graph shows a decrease in TLT following acquisition trial in the arsenic group and its restoration in arsenic þ noggin group in passive avoidance test. B, Representative bar graph shows an increase in the number of errors (%) during learning, and a fall in memory retained (% saving memory) in the arsenic group and its restoration in arsenic þ noggin group when assessed at 24 h, 48 h, and 7th day post-learning in YMaze test. Data represent means 6 SE of 7 rats. ***P < .001 and *P < .05, compared with vehicle (V) or as indicated.
from attenuated hippocampal neuronal apoptosis, and our results also point to an ameliorative role of hippocampal noggin infusion against overall neuronal apoptosis-induced hippocampal neurodegeneration.
Beyond BMP signaling, the current study also probed into the status of BDNF neurosurvival pathway following arsenic exposure. Evidence of an arsenic-mediated induction of cerebral apoptosis involving reduced BDNF signaling has been shown during axonal demyelination within the corpus callosum, and that too in the developing rat brain (Rai et al., 2013) . Moreover, the same study focused upon heavy-metal mixtures rather than individual arsenic (Rai et al., 2013) . In terms of the hippocampus, although our arsenic-mediated decrease in BDNF expression appeared relatively less novel, nonetheless, prior reports mainly dealt with a down-stream cAMP-response element binding protein (CREB) signaling Tyler and Allan, 2014) . BDNF has a strong link with TrkB that arbitrates trophic support to adult neurons, and a decreased expression of the receptor associates with cell loss (Kadri, 1992) . Moreover, BDNF/TrkB signaling controls synaptic plasticity and long-term potentiation, resulting from regulated hippocampal neuronal apoptosis (Hughes et al., 1999) . Upholding these concepts, the current study enlightens a decreased BDNF-dependent TrkB pathway within the hippocampal neurons following arsenic exposure, and appropriately relates it with apoptosis, increased neuronal loss and an ultimate cognitive impairment. Thus, in addition to an identified role of arsenic in engendering anxiety and depression-like behavior via attenuated cerebral BDNF/TrkB (Chang et al., 2015) , this study provides an explicit linkage between aberrations in this signaling pathway and typical behavioral functions of the hippocampus. Notably, our study also offers a defined link between the reduced BDNF/TrkB and augmented BMP/Smad signaling. A combined functioning of BMP and BDNF against stress is well-established (Chaverneff and Barrett, 2009; Gratacos et al., 2001; Watanabe et al., 2016) , and the same has been observed in the hippocampal neurons as Figure 9 . Schematic: Arsenic enhances hippocampal neuronal apoptosis and cognitive impairment involving increased BMP2-dependent attenuated BDNF/TrkB signaling. Arsenic activates BMP pathway, marked by enhanced BMP2 and BMPR2 expression and increased p-Smad1/5 signaling within the hippocampal neurons within the brain. The increased BMP2/Smad signal suppresses BDNF expression and a BDNF-dependent TrkB pathway, inducing cleaved Caspase-3 and PARP-mediated apoptosis of the hippocampal neurons and thereby cognitive deficits in the arsenic-treated rats. Noggin treatment blocked this arsenic-mediated enhancement in BMP2/Smaddependent reduced BDNF/TrkB pathway and neuronal apoptosis within the hippocampus, restoring cognitive performances.
well (Babu et al., 2007; Nonner et al., 2001) . Disparate views have emerged related to this, where one proposed a complementarity between the two (Babu et al., 2007; Chaverneff and Barrett, 2009) and another stated that BMP enhanced the neurotrophin expression (Galter et al., 1999; Gratacos et al., 2001) . Interestingly, one of the studies also showed that BDNF as such was capable of promoting BMP/Smad activation (Chaverneff and Barrett, 2009) . However, compared with all these reports, our findings stand very distinct, demonstrating an inverse relation between the two signaling pathways, where increased BMP suppressed the BDNF signaling. Strikingly, opposing a prior finding that depicted that the trophic effects of BMPs manifested exclusively in the presence of increased BDNF (Nonner et al., 2001) , our study demonstrated the indispensability of an attenuated BDNF for BMP-dependent pathological functions in hippocampal neurons. A valid explanation that may justify the discrepancy appears that, unlike the current study, the previous studies mainly focused upon neuroprotection, where BMP and BDNF in unison reduced neuronal stress and increased neurological performance (Chaverneff and Barrett, 2009; Galter et al., 1999; Gratacos et al., 2001) . A study also demonstrated a synergistic protective effect of BDNF and BMP that occurred upstream of reduced caspase activation (Nonner et al., 2001) . Thus, our observed inverse link between BMP2 and BDNF signaling may be presumed as a unique feature toward increased hippocampal neuronal apoptosis and could also be speculated as exclusive for heavy-metal toxicants, or arsenic as such. Another explanation may be based on the fact that BMP/Smad pathways interact with transcription factors and transmit diverse signals within the brain (Chaverneff and Barrett, 2009; Takatoh and Wang, 2012) . Taking clue from this, it may be assumed that in the current situation, arsenic-induced BMP/ Smad signaling induces transcription of target genes that repress BDNF expression, and hence attenuate BDNF/TrkB signaling toward hippocampal neuronal apoptosis. Reduced hippocampal neurogenesis has also been cited as a key reason for arsenic-induced neurotoxic effects Tyler and Allan, 2013) . Supportively, we observed an attenuation in neurogenesis in the arsenic-treated hippocampus (Supplementary material 5). Additionally, we also found that noggin and BDNF could restore the hippocampal neurogenesis (Supplementary material 5), suggesting that arsenic may be capable of disrupting the intricate balance between neuronegesis, neuronal survival and apoptosis, with the probable participation of BMP and BDNF pathways. Nonetheless, the concept of Smad-dependent transcriptional regulation of BDNF expression and link between BDNF, BMP, neurogenesis and neuronal viability stand hypothetical, and are being actively explored by our group, particularly for arsenic exposures.
Supporting the concept of hippocampal neurodegeneration (Carroll et al., 2017; Jing et al., 2012; Ramos-Chavez et al., 2015) , our study shows an arsenic-mediated cognitive decline, and clearly provides a link with an aberrant BMP-dependent mechanism. Besides the participation of dysfunctional glutamate metabolism (Huo et al., 2015) , muscarinic-cholinergic functioning (Chandravanshi et al., 2014) , Ca (2þ) /calmodulin-dependent protein kinase IV , etc. arsenic has been related to an attenuated hippocampal BDNF/CREB-mediated learning-memory impairment, which could be averted through restored BDNF levels . The current study using arsenic and noggin as a tool additionally helped identifying an upstream pathway in the form of BMP2/Smad, which deregulated this BDNF-dependent cognitive maintenance. This observation not only summarized our entire finding, linking the altered signaling pathways and functional read out following arsenic exposure, but also offered a novel mechanism for cognitive loss. Thus, the present study provides a clear rationale and mechanism justifying gains in learning upon physical activity (exercise) in neuron specific enolase-noggin transgenic mice reported earlier (Gobeske et al., 2009) .
CONCLUSION
This study establishes augmented BMP2/Smad-dependent attenuated down-steam BDNF/TrkB as a key pathway towards hippocampal neurodegeneration. Thus, suppression of BMP2/Smad signaling seems extremely important in maintaining hippocampal functions, and its targeted inactivation by noggin may be proposed as a key route towards attenuating cognitive failures, especially in arsenic-exposed conditions.
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